---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-015708"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:33:11.394769+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Hookipa Q3 net loss narrows to $13.8M; cash $60M; Phase 2 eseba-vec enrollment complete (68 pts)

## Summary
- Net loss $13.8M vs $19.1M YoY; revenue $4.7M (down from $6.9M) on Roche collaboration termination.
- Cash $60.0M at Sep 30, 2024 (from $117.5M Dec 2023); received $5M milestone from Gilead for HB-500 dosing.
- Phase 2 eseba-vec + pembrolizumab in HPV+ HNSCC enrolled 68 patients ahead of schedule; updated data at SITC 2024.
- First patients dosed in MSKCC Investigator Initiated Trial of eseba-vec as adjuvant therapy for HNSCC.
- Leadership: Malte Peters appointed CEO, Terry Coelho CFO in July; reverse stock split effected 1:10.

## SEC filing metadata
- accession: 0001558370-24-015708
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837024015708/0001558370-24-015708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837024015708/hook-20241114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-015708
- JSON: https://secwatch.observer/filing/0001558370-24-015708.json
- Plain text: https://secwatch.observer/filing/0001558370-24-015708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.